CASI Pharmaceuticals

SEC Filings

SEC Filings

View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. CASI Pharmaceuticals, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the information contained therein. Further, CASI Pharmaceuticals, Inc. takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.

Financial Reports

Date Form Description Web XBRL
November 14, 2016 10-Q Quarterly Report
August 15, 2016 10-Q Quarterly Report
May 13, 2016 10-Q Quarterly Report
March 28, 2016 10-K Annual Report
November 13, 2015 10-Q Quarterly Report
August 14, 2015 10-Q Quarterly Report
May 15, 2015 10-Q Quarterly Report
March 27, 2015 10-K Annual Report
November 14, 2014 10-Q Quarterly Report
August 14, 2014 10-Q Quarterly Report
May 15, 2014 10-Q Quarterly Report

In order to read our interactive data filings, you will need an XBRL viewer such as the viewer provided by the SEC at www.SEC.gov.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →